[Tree] Verve Therapeutics pauses gene-editing trial on safety concerns

Version 0.09 (2024-04-02 12:18:56.150000)

updates: Verve Therapeutics pauses gene-editing trial on safety concerns, shares tumble

  • ➔
Version 0.08 (2024-03-22 20:19:33.236000)

updates: FDA approves expanded labels for Esperion's cholesterol drugs, offering cardiovascular risk reduction in primary and secondary prevention patients

  • ➔
Version 0.07 (2024-03-22 16:36:19.402000)

updates: FDA approves first medication for MASH

  • ➔
  • ➔
  • ➔
  • ➔
Version 0.06 (2024-03-14 22:24:46.478000)

updates: Add information about the FDA approval of Rezdiffra for fatty liver disease

  • ➔
  • ➔
  • ➔
Version 0.05 (2024-02-28 18:25:57.161000)

updates: The story now includes information about the potential of vorinostat in stroke recovery

  • ➔
  • ➔
Version 0.04 (2023-10-25 14:53:59.228000)

updates: Restructured and streamlined information for clarity and coherence

  • ➔
Version 0.03 (2023-10-22 12:03:03.367000)

updates: Updated information on Arvinas' PROTAC AR Degraders in mCRPC

  • ➔
Version 0.02 (2023-10-21 05:59:36.874000)

updates: The new narrative provides more specific details and emphasizes the promising nature of the data

  • ➔
Version 0.01 (2023-10-21 05:53:15.817000)

updates: The narrative has been reorganized and condensed for clarity and coherence

  • ➔
Version 0.0 (2023-10-08 15:01:27.179000)

updates:

  • ➔
  • ➔